Francesca Barone - 03 Feb 2022 Form 3 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Chief Scientific Officer
Signature
/s/ John Canepa, as Attorney-In-Fact for Francesca Barone
Issuer symbol
CADL
Transactions as of
03 Feb 2022
Net transactions value
$0
Form type
3
Filing time
07 Feb 2022, 16:35:13 UTC
Next filing
01 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CADL Common Stock 1,500 03 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CADL Stock Option (Right to Buy) 03 Feb 2022 Common Stock 48,822 $1.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option vested and became exercisable on December 30, 2021, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.